
Brexi0.5 mg
Eskayef Bangladesh Ltd.
Brexpiprazole is an atypical antipsychotic (serotonin-dopamine activity modulator) indicated for: FDA-approved (established) indications Schizophrenia — for the treatment of schizophrenia in adults…
Brexpiprazole is an atypical antipsychotic (serotonin-dopamine activity modulator) indicated for:
Important distinction: Brexpiprazole is not approved for the treatment of psychosis related to dementia (dementia-related psychosis); see Precautions and Warnings regarding the boxed mortality warning in elderly dementia patients.
Brexpiprazole has been studied off-label for other psychiatric indications (e.g., as an add-on in certain anxiety or agitation states), but such use is not FDA-approved and should only be undertaken under specialist psychiatric supervision.
| Indication | Starting dose | Titration | Target / maximum dose |
|---|---|---|---|
| Schizophrenia (adults) | 1 mg once daily (days 1–4) | Increase to 2 mg/day on day 5; adjust weekly thereafter based on response/tolerability | Target 2–4 mg/day; maximum 4 mg/day |
| Schizophrenia (adolescents 13–17 years) | 0.5–1 mg once daily | Gradual weekly increases as tolerated | Target 2–4 mg/day; maximum 4 mg/day |
| Adjunctive therapy for major depressive disorder (adults) | 0.5–1 mg once daily | Increase by 1 mg at weekly intervals as tolerated, added to an existing antidepressant | Target 2 mg/day; range 1–3 mg/day; maximum 3 mg/day |
| Agitation associated with Alzheimer's dementia (adults) | 0.5 mg once daily for 7 days | Increase to 1 mg/day for 7 days, then may further increase based on response | Target dose commonly 2 mg/day; maximum 3 mg/day |
See Contraindications and Precautions and Warnings for safety information relevant to dosing decisions.
| Indication | Frequently reported side effects |
|---|---|
| Schizophrenia | Akathisia, weight gain, headache, somnolence, increased appetite, insomnia |
| Adjunctive MDD | Akathisia, weight gain, nausea, diarrhea, fatigue, headache |
| Alzheimer's dementia agitation | Headache, insomnia, urinary tract infection, somnolence, dizziness |
Serious but less common reactions (neuroleptic malignant syndrome, tardive dyskinesia, seizures, severe allergic reactions) are discussed under Precautions and Warnings — seek prompt medical attention if these occur.
Brexpiprazole is contraindicated in patients with known hypersensitivity to Brexpiprazole or to any component of the formulation. Hypersensitivity reactions (including anaphylaxis and angioedema) have been reported.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.